Literature DB >> 8759053

Tissue repair in the iris in experimental autoimmune uveoretinitis.

J Wang1, E Essner, H Shichi.   

Abstract

Our previous work on rats with S-antigen-induced experimental autoimmune uveoretinitis showed iris tissue changes involving infiltration of inflammatory cells, destruction of the iris architecture, and breakdown of the blood-retinal barrier. The present study reports the remarkable ability of the iris to regenerate during the postinflammatory period. The iris regenerates 50% of its architecture by Day 20 postimmunization. The number of lymphocytes and polymorphonuclear leukocyte (PMNs) was relatively high at this stage. Many capillaries showed abnormal endothelial cells. Unmyelinated nerve axons were often seen near blood vessels. The iris stroma was edematous. By Day 30, approximately 95% of the iris had regenerated, the number of lymphocytes and PMNs decreased, and the number of macrophages increased. Most capillaries looked normal and numerous axons in different stages of myelination were apparent. The stroma, the dilator muscle, and the posterior epithelium were almost completely restored. By Day 45, the iris appeared to be virtually normal. Most striking was the abundance of myelinated nerve axons located near blood vessels. Type I collagen immunoreactivity in vascular endothelial cells increased from Day 20 to Day 60 postimmunization, suggesting that blood vessel endothelial cells may play a role in collagenization of the iris stroma.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8759053     DOI: 10.1006/exmp.1995.1029

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  1 in total

1.  Distinct iris gene expression profiles of primary angle closure glaucoma and primary open angle glaucoma and their interaction with ocular biometric parameters.

Authors:  Li-Fong Seet; Arun Narayanaswamy; Sharon N Finger; Hla M Htoon; Monisha E Nongpiur; Li Zhen Toh; Henrietta Ho; Shamira A Perera; Tina T Wong
Journal:  Clin Exp Ophthalmol       Date:  2016-05-02       Impact factor: 4.207

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.